Eli Lilly prepares obesity efforts with future hope – goes down same path as Novo Nordisk

US Eli Lilly is testing its weight loss and glucose control drug candidate Tirzepatide, joining Novo Nordisk on the obesity market for the first time. The road to commercialization will look a lot like that of Novo Nordisk, says Eli Lilly executive.

Ever since Novo Nordisk entered the obesity market in 2015, its management and investors have hoped for another pharmaceutical firm to accompany it and help establishing and focusing on the market for relevant treatments.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading